Cash from Financing (Quarterly) Chart

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2020. Start Trial.
Date Value
September 30, 2026 -5.00M
June 30, 2026 -12.00M
March 31, 2026 -38.00M
December 31, 2025 -187.00M
September 30, 2025 -76.00M
June 30, 2025 -223.00M
March 31, 2025 -75.00M
December 31, 2024 -82.00M
September 30, 2024 -78.00M
June 30, 2024 -134.00M
March 31, 2024 -74.00M
December 31, 2023 -77.00M
September 30, 2023 -78.00M
June 30, 2023 -88.00M
Date Value
March 31, 2023 -326.00M
December 31, 2022 -82.00M
September 30, 2022 -77.00M
June 30, 2022 -183.00M
March 31, 2022 -91.00M
December 31, 2021 -379.00M
September 30, 2021 338.00M
June 30, 2021 -700.00M
March 31, 2021 -592.00M
December 31, 2020 -506.00M
September 30, 2020 -474.00M
June 30, 2020 -577.00M
March 31, 2020 -618.00M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Viatris, Inc. -289.80M
Pacira Biosciences, Inc. -69.77M
ANI Pharmaceuticals, Inc. -9.829M
Corcept Therapeutics, Inc. -23.88M
Veru, Inc. -0.0519M